In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Equillium (EQ), with a price target of $14.00. The company’s shares closed last Monday at $10.05.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 6.8% and a 44.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Equillium is a Moderate Buy with an average price target of $19.00.
See today’s analyst top recommended stocks >>
Based on Equillium’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.84 million. In comparison, last year the company had a GAAP net loss of $5.95 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
Read More on EQ:
